MiMedx Group Files Proxy Statement Related To 2022 Annual Shareholder Meeting

Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have Established Strong, New Foundation for Growth

Company Urges Shareholders to Vote “FOR” Both Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D. – on the WHITE Proxy Card

MARIETTA, Ga., May 18, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (NASDAQ:MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its 2022 Annual Meeting of Shareholders, which is scheduled to be held on June 7, 2022. The presentation, and other important shareholder materials, are available at www.VoteMIMEDX.com. 

In the presentation, MIMEDX outlines the significant progress the Company has made over the last three years under its current leadership team and provides transparency around a number of topics and initiatives pertinent to shareholders, including:

• Strategy for Long-Term Value Creation: MIMEDX has taken decisive action to successfully sustain, stabilize and grow the Company over the last three years, and has a clear strategy for long-term shareholder value creation. MIMEDX recently announced a third consecutive quarter of double-digit growth in its Advanced Wound Care & Surgical Recovery products, demonstrating strong execution. In addition, the realignment of the Company’s internal business structure positions MIMEDX to further expand, innovate, and drive sustained growth, and also accelerate the start of trial enrollment in its Knee Osteoarthritis clinical trial program.

 

• Corporate Governance Practices and Board Qualifications: MIMEDX’s Board has been entirely reconstituted since 2019 and is made up of nine highly qualified directors with the critical skills, life-sciences experience and business acumen to oversee the Company’s strategy. The Board has adopted approximately 70 best-practice and shareholder friendly corporate governance reforms over the last three years and resolved all legacy Company issues, demonstrating its commitment to best-in-class governance practices.

 

• Executive Compensation: MIMEDX’s executive compensation, determined in partnership with an independent consultant, is based on a philosophy of organizational and individual performance and is aligned with shareholder value through performance factors, including revenue growth, and significant equity-based portions of total compensation. It is well within the range of MIMEDX peers and is closely aligned with shareholder interests. For example, in part due to the decline in the Company’s stock price, none of MIMEDX’s executive officers received annual cash bonuses at their 2021 target levels.